Bioprocessing
Upstream, downstream, scale-up and biomanufacturing.
Latest Bioprocessing news
GALY Advances Biomanufacturing Platform to Build a New Supply Chain for Cocoa and Other Global Commodities
Read at StreetInsider →Disturbance shifts microbial assembly patterns in engineered bioreactors, study finds
Read at EurekAlert! →Eli Lilly and Amplitude Therapeutics partner to manufacture RNA vaccines
Read at BioProcess International →SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing
Read at Select Science →Polyethylene Film Aseptic Market Growth to 2035 Driven by Single-Use Bioprocessing Adoption - News and Statistics
Read at IndexBox →From Phase 3 to Commercialization: What Sponsors Need from a Sterile Injectable CDMO
Read at Contract Pharma →From the knowledge base
What did we learn from Big Pharma’s Q2 results?
Fierce editors break down Big Pharma’s second-quarter results, from AI and new leadership to the oral GLP-1 race and potential new blockbusters.
Regulatory tracker: J&J scores EU approval for Tecvayli-Darzalex combo
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
The Oral GLP-1 Tracker: Novo's Wegovy pill back on track as Lilly's momentum slows
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.
Lundbeck continues neuroscience evolution as CEO keeps company ‘punching above its weight’
Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a “neuroscience challenger” capable of “punching above its weight.”
Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’
Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a “safety event,” although the German pharma isn't shedding light on the nature of the incident for now.
Why Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circling
Pheast Therapeutics may have learned the hard way about the risks of competitors getting a glimpse of your heard-earned discoveries, but the immuno-oncology startup is so far sticking to its transparent approach.